Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents

Reinier Cornelis Anthonius van Linschoten, Elyke Visser, Christa Diana Niehot, C. Janneke van der Woude, Jan Antonius Hazelzet, Desirée van Noord, Rachel Louise West

Summary
Background: Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health policy makers worldwide.

Aim: To assess the cost of illness of IBD from the societal perspective taking into account time trends and geographical differences.

Methods: A systematic review of all population-based studies on cost of illness of IBD published in Embase, Medline, Web of Science and Google Scholar. Methodology of included studies was assessed and costs were adjusted to 2018 US dollars.

Results: Study methodologies differed considerably, with large differences in perspective, valuation method and population. For prevalent Crohn's disease (CD) cases in the last ten years annual healthcare costs were in Asia $4417 (range $1230-$31 161); Europe $12 439 ($7694-$15 807) and North America $17 495 ($14 454-$20 535). For ulcerative colitis (UC), these were $1606 ($309-$14 572), $7224 ($3228-$9779) and $13 559 ($13 559-$13 559). The main cost driver was medication, the cost of which increased considerably between 1985 and 2018, while outpatient and inpatient costs remained stable. IBD had a negative impact on work productivity. Annual costs of absenteeism for CD and UC were in Asia (with presenteeism) $5638 ($5638-$5638) and $4828 ($4828-$4828); Europe $2660 ($641-$5277) and $2394 ($85-$2350). North America $752 ($307-$1303) and $1443 ($85-$2350).

Conclusion: IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.
1 | INTRODUCTION

Biologics and small molecules are increasingly used and are potent agents for the treatment of inflammatory bowel disease (IBD). As shown in randomised clinical trials, these drugs are efficacious in inducing clinical remission, improving work productivity, and reducing hospitalisation and surgery rates. They are expensive however, potentially costing over $10 000 per treatment year depending on country and access to biosimilars, and could increase the cost burden on the already strained healthcare systems worldwide.

Two systematic reviews were published on the costs of Crohn’s disease (CD) and ulcerative colitis (UC) in Europe and North America in 2008 and 2010 respectively. Since then, many new treatment modalities have become available, and numerous studies on the costs of IBD have been published. Reviews on the indirect costs of IBD and costs for the paediatric population have been published since, but no comprehensive review on the cost of illness of IBD has been carried out.

With the increasing incidence and prevalence of IBD outside the Western world, knowledge on the economic burden and cost drivers is essential for health policymakers worldwide. This requires a systematic assessment from a societal perspective, which includes the costs of healthcare, patients own financial contribution and work impairment, such as absenteeism and presenteeism.

We aimed to estimate the global economic impact of IBD and therefore conducted this systematic review of the cost of illness of IBD from a societal perspective and determined cost drivers over a 30-year time period (1985-2018) in different geographical areas.

2 | MATERIALS AND METHODS

2.1 | Protocol and registration

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The review protocol was prospectively registered in PROSPERO under CRD42020158567.

2.2 | Eligibility criteria

Eligible for inclusion in the systematic review were observational studies published in peer-reviewed journals on healthcare, productivity or patients costs of patients with CD, UC, IBD-unclassified/indeterminate (IBD-U), or a combination of these diseases. Studies on interventions and those reporting costs only for a subset of patients defined by phenotype or treatment were excluded, as they do not give a representative estimate of the cost-of-illness of IBD. According to the PRISMA statement, the eligibility criteria were published beforehand. During the conduct of the systematic review, the protocol was changed because a systematic review on cost of illness in children was published during the conduct of this systematic review. After the change, only studies on an adult population and studies on a combined population of both adults and children were eligible. Studies reporting costs for a population younger than 18 years of age were excluded. Studies in other languages than English were excluded, as were all conference abstracts and posters. No limit on publication date was applied.

2.3 | Search and information sources

A systematic search to find relevant articles was performed in cooperation with an information specialist of the medical library in four databases: Embase, Medline (Ovid), Web of Science and Google Scholar. For Google Scholar, it was decided a priori to only include the first 200 results to limit the proportion of articles that are not formally published in journals. A single search string query was used to search the databases for reproducibility and adaptability (see File S1). For retrieval in Google Scholar, the programme Publish or Perish (version 7.19) was used. During the search, the queries were refined to only retrieve articles in English and to exclude animal studies and conference abstracts. The search was performed on 28 August 2019 and updated on 20 January 2020 and on 11 June 2020. This could affect the retrieved references as the amount or relevance ranking can differ due to either added or redacted index terms or due to a changed relevance ranking (as seen with Google Scholar). The retrieved studies were crosschecked with the reference lists of the prior published reviews to search for missing studies.

2.4 | Study selection

Two independent reviewers (RvL and EV) reviewed all studies found in the initial search on title and abstract. Subsequently, the studies that met all eligibility criteria were independently screened on full text by the two reviewers. In case of disagreement, the article was discussed until consensus was reached. These articles are marked with an asterisk in the results.

2.5 | Data collection and items

The two aforementioned reviewers separately collected the data from the included studies using a case report form developed for this review. In case of disagreement, inconsistencies were corrected by jointly returning to the article in question. For each study, the following data were collected: cost sectors, cost components, method of quantifying resource use, method of valuating costs and results with a measure of spread (e.g., mean and standard deviation). Metadata were collected on general study aspects (title, authors, year of publication), disease population, perspective, currency and period and country of data collection.

If the perspective from which resource use and valuation was not made explicit by the study, it was determined from the study...
methodology. When the currency year was not stated, the final year of follow-up was used. When cost data were collected for a period longer than a year and reported as a single estimate, we treated this estimate as representative for the middle of the period when graphing the data.

2.6 | Bias

The main risk of bias lies at the level of individual studies because of the widely different methods used in these studies. Methodology and risk of bias were assessed by two reviewers (RvL and EV) independently using the tool published by Larg and Moss. 

2.7 | Synthesis of results

Where cost data were not available per patient, the per patient cost was calculated from the total costs and patient numbers. To compare results, all costs were converted to 2018 United States (US) dollars using the gross domestic product (GDP) deflator (preferred measure to adjust for inflation from the societal perspective) and purchasing power parity (PPP) as defined by the World Bank. Where World Bank estimates were not available, GDP deflator and PPP as defined by the Organisation for Economic Co-operation and Development (OECD) were used. For Taiwan and Hong Kong, the GDP deflator published by their respective office for national statistics was used. For Taiwan, PPP as defined by the International Monetary Fund was used. 

Because of heterogeneity between studies, no formal meta-analysis was attempted, but descriptive summaries are given. All costs are reported as annual costs per patient per year. Where possible, healthcare costs were divided into three different categories: inpatient included the cost of hospital admissions and surgery; outpatient included the cost of physician or emergency room visits, outpatient diagnostics and outpatient surgery; and medication included costs for biologic and non-biologic therapy. Work productivity costs were categorised as absenteeism (sick leave), presenteeism (reduced efficiency at work), early retirement or disability, unpaid time loss or caregiver productivity loss.

Studies that distinguished between CD and UC cohorts are reported under the respective disease category while studies that aggregated CD and UC patients are reported under IBD.

To assess changes in cost components over time (1985-2018), only studies that reported means for all three components (inpatient, outpatient and medication) were included. If multiple studies reported a distribution of cost components for a given year, the average distribution of the studies was used. To determine the present-day annual healthcare costs of prevalent IBD patients, all studies reporting on the mean cost of prevalent IBD patients were used. The proportion of biologic users per study was compared with healthcare costs for all studies reporting mean healthcare costs and the proportion of patients on biologics. To compare productivity costs with healthcare costs, only studies that estimated mean healthcare costs and any category of mean productivity costs were included.

3 | RESULTS

3.1 | Study selection

The systematic search identified 7566 studies, of which 2729 were removed because of duplication. The remaining 4837 studies were screened on title and abstract and 4730 excluded. After full-text screening, 64 of the remaining 107 studies were included in the systematic review. No missed studies were found in the reference lists of the other systematic reviews. For the study selection process and reasons for exclusion, see the PRISMA flowchart (Figure 1). Cohen’s kappa for inclusion of a study was 0.88. The reduced kappa can be explained by one of the reviewers’ learning curve. After comparing the decisions made by both reviewers, there was no disagreement on which studies should be included in the study.

3.2 | Study characteristics

An overview of the study populations is presented in Table S1. A detailed overview of the study characteristics, methodologies, results and the summaries that each study contributed to can be found in File S2. Of the 64 studies, seven were performed in Asia, 29 in Europe, 26 in North America (United States and Canada) and two in Oceania. Most studies (54) used a prevalence-based approach. Of these, five studies applied a top-down costing method and the others a bottom-up approach. All 11 incidence-based studies used a bottom-up costing method. One study reported costs for both a prevalent as well an incident cohort. Only three studies reported on the costs of IBD-U (File S2).

The studies covered a time period of more than 30 years (1985-2018). Study timeframes differed considerably. Some studies were cross-sectional with a 1-week recall period to determine costs, while others were longitudinal with a time period of up to 10 years. For most incidence-based studies, costs in the first year after diagnosis could be calculated. Three incidence-based studies reported the annual costs over a 10-year period.

The perspectives from which resource use and valuation were determined varied. Twenty studies used the third-party payer perspective, using insurance charges or payments as costs. The employer perspective, focusing on the value of productivity foregone because of IBD, was used in seven studies. The healthcare system perspective, determining the impact of IBD on healthcare costs, was used in 15 studies. In addition, four studies took the government perspective, examining healthcare costs from the perspective of a government-funded healthcare system and productivity costs. Seventeen studies adopted a societal perspective, estimating all
costs no matter who incurred them. The perspective of one study remained unclear.40

IBD-attributable costs were determined by 55 studies. This was done by either matching a control group, adjusting for differences between IBD- and non-IBD cases in a regression analysis, or counting IBD-attributable resource use. Nine studies reported all healthcare costs incurred by IBD patients.32,44,47,50,53,56,68,82 The methods to determine and value resource use and productivity losses differed considerably. Five studies reported median costs per patient, and one study reported mean healthcare costs but median productivity costs.35,44,47,59,68

3.3 | Healthcare costs

The reported healthcare costs varied considerably between studies and geographical regions. The annual mean healthcare costs for prevalent and incident cases of IBD, CD and UC are summarised in Table 1. Changes in mean annual healthcare costs and component costs over the 30-year time period for total IBD, CD and UC are presented in Figures 2-4.

The means of the reported mean annual healthcare costs for prevalent cases of IBD, CD and UC were between $1051 and $3755 in Asia; $5938 and $10 484 in Europe; and $8053 and $13 212 in North America. No studies from Oceania reported mean healthcare costs, but median healthcare costs were estimated to be between $3700 and $11 340 (File S2). Annual mean healthcare costs per prevalent case of IBD, CD and UC seem to be increasing in Asia, Europe and North America. Longitudinal studies from Europe and Asia show that this increase is mostly driven by an increase in medication costs.65,81

Over the 30-year period, cost drivers have shifted from inpatient to medication costs for IBD in general, CD and UC (Figure 5A-C and Figures S1-S3). This cost trend is primarily attributable to an increase in medication costs, while inpatient and outpatient costs were relatively stable during the same time period. This was seen in Europe and North America, as no studies from Asia or Oceania were eligible for this analysis. For the comparison between proportion of biologic users and mean healthcare costs per study, see Figures S4-S6.

The mean present-day IBD-attributable healthcare costs differed considerably between geographical areas (Table 2). In most cases, the primary cost driver was found to be medication, except for North America, where outpatient costs were the main cost driver.

Longitudinal data to assess changes in total and component costs for incident cases were not available for different time periods. Most studies reported annual healthcare costs for incident cases in the time period 2008-2012,42,47,70,71,73,76,92,93,95 and other incidence-based studies reported healthcare costs in the first ten years after diagnosis.67,77

Mean annual IBD-attributable costs of incident CD and UC cases in the first year after diagnosis were assessed in seven studies (Table 3).42,70,73,76,92,93,95 Three of these studies were conducted

FIGURE 1 PRISMA flow diagram depicting study selection
in Europe,\textsuperscript{42,92,93} of which two reported on different timeframes for the same patient population.\textsuperscript{42,92} Costs reported in the more comprehensive of the two studies were used.\textsuperscript{92} Cost drivers differed per study but were mostly either inpatient or outpatient costs. Medication was the main cost driver for the study in Australia. Costs for incident cases were found to be between $700 (+35\%) and $1000 (+55\%) higher than for prevalent cases.\textsuperscript{70} This was mostly because of the higher costs for diagnostics and surgery for the incident cases, notwithstanding a lower cost for biologic therapy for incident CD cases. Costs for incident cases peaked in the first year after diagnosis, and then quickly declined and stabilised after two years, driven by a decrease in hospitalisation, surgical and investigation costs. However, the cost decline is partially offset by increased costs for biologics each year after diagnosis.\textsuperscript{70,71,73,77,92,93}

### 3.4 | Productivity costs

The annual mean productivity costs for prevalent and incident cases of IBD, CD and UC are summarised in Table 4. The comparison between healthcare costs and productivity costs can be found in Figures S7-S9. Less than half of the studies (n = 25) reported on productivity costs and those studies mainly focused on absenteeism. Productivity was measured in most studies\textsuperscript{63,64,74,75,89,90,94} with the Work Productivity and Activity Impairment (WPAI) questionnaire, and one study\textsuperscript{58} developed their own survey to measure presenteeism. The productivity costs and components reported in the studies varied considerably. All studies used the human capital approach either implicitly or explicitly.

Costs were found to be highest in North America ($20 074), mostly driven by presenteeism.\textsuperscript{90} Only one study reported on absenteeism and presenteeism in Asia, and no studies were done in
Oceania. Studies in Europe estimated a broader range of productivity costs, also reporting on early retirement or disability, loss of unpaid time and caregiver absenteeism. Annual costs of unpaid time loss in Europe for CD patients were estimated to be $3390 (range $866-$5914). Annual caregiver productivity costs were estimated for both CD and UC patients in Europe and were respectively $468 ($98-$837) and $83 ($83-$83).

### 3.5 | Patient costs

A large range of IBD-attributable patient costs were reported, including diet, equipment, informational material, hygiene articles, alternative therapy, household support, patient activities, insurance deductible and over-the-counter (OTC) drug use. Only eight studies (all in Europe) reported on patient costs with mean annual costs of $582 for CD ($81-$1927) and $497 ($181-$1341) for UC.

### 4 | DISCUSSION

#### 4.1 | Healthcare costs

Societal cost of illness of IBD appears to be increasing worldwide, with the highest costs in North America and the lowest costs in Asia. This increase seems to be mainly caused by increasing medication costs while inpatient and outpatient costs remained stable. While there are considerable differences in total costs per patient per geographical region, the increasing trend over time can be seen in all geographical regions.

Costs in Asia are reported to be considerably lower than those in Europe and North America. It is unclear whether this is caused by relatively lower uptake of biologics, as most studies in Asia did not report the proportion of patients on biologic therapy. The only study from Asia that looked at cost drivers was done in Korea and attributed these costs to biologics, as these costs rapidly increased over time and accounted for 48.8% and 68.8% of the total costs for UC and CD respectively in 2015. Higher costs were reported in the Iran study compared to all other studies reviewed. A possible explanation is the current economic instability in Iran, leading to biased estimates compared to other countries. Costs were not reported in the local currency and component costs added up to more than 200% of the total reported costs. The drivers of these high costs are unclear.

In Europe, cost trends were highest in Switzerland, while in the Netherlands and Serbia the annual cost per patient was considerably lower. This difference is most likely driven by differing uptake of biologic therapy with the proportion of patients on biologic therapy being the highest in Switzerland. Healthcare costs reported in North America fluctuated widely, partly because of within-region differences in study methods. While...
some studies used the Medical Expenditure Panel Survey (MEPS) to determine costs, most studies used health insurance databases, which contain only insured patients and thus might not adequately reflect the entire IBD population. Moreover, the case-finding method used in the insurance-based studies skews the patient population towards higher disease severity. As patients were identified using ICD-9 or ICD-10 claim codes for IBD with a claim-free pre-index period of 6-12 months, only patients who used healthcare during the study period were identified, and those in remission were excluded.

The increasing economic burden of biologic therapy is not an IBD-specific problem. A recent systematic review on the cost of illness of rheumatoid arthritis also reported a shift in cost drivers from inpatient to medication costs. Direct comparison of annual costs per patient between diseases is hampered by the heterogeneity in included studies in both reviews, leading to broad ranges of costs.

Increasing use and costs for biologic therapy are probably driven by acceptance of a treat-to-target approach that has shown to improve outcomes. The question remains however whether such an approach is also cost-effective, as incremental cost-effectiveness ratios of biologic therapy often exceeded $100,000 per quality-adjusted life year.

The introduction of biologic therapy was expected to improve disease control and reduce hospitalisations and surgery and consequently reduce inpatient costs. Earlier reports claimed that healthcare costs did not increase, but cost components shifted from inpatient to medication. Our systematic review shows that while medication costs have increased, inpatient costs do not seem to be declining. These findings are in line with earlier studies that found little to no association between biologic use and hospitalisation or surgery rates at population level. The discrepancy between randomised controlled trials and real-world evidence is cause for concern, as the market share of biologic agents is increasing, and the real-world effect on healthcare use is doubtful. Future initiatives need to focus on increasing value by optimising the use of biologics in daily practice and consequently improve effectiveness and reduce costs.

![FIGURE 3](image)  
Mean annual healthcare costs per prevalent Crohn’s disease case in 2018 US dollars. Lines indicate longitudinal studies. Numbers indicate corresponding reference.
4.2 | Productivity costs

Productivity costs are a key IBD cost burden, with absenteeism and presenteeism being a substantial proportion of the total costs. Productivity losses can exceed healthcare costs when factors such as early retirement, disability and unpaid time loss are taken into account. Only a few studies assessed productivity costs and most of these studies only reported on absenteeism. Because few data are available, time trends in productivity costs and consequently the effect of the introduction of biologics on productivity costs could not be assessed. The high societal burden of productivity costs and uncertainty around these estimates call for research on IBD-related productivity costs, especially presenteeism, early retirement, and unpaid time loss.

The impact of IBD on societal productivity costs might be lower than indicated in the studies included in this systematic review. While all studies used the human capital approach to value productivity losses, there is a debate on whether the friction cost method should be used to determine productivity costs from the societal perspective. The human capital approach incorporates all productivity lost due to a disease over a patient’s lifetime, while the friction cost method only counts the losses during the time period required to replace an incapacitated worker. The friction cost method leads to lower estimates because costs for long-term disability are restricted to the friction cost period. This was also seen in rheumatoid arthritis, where cost-effectiveness of biologic agents was related to the valuation method used. For IBD, little is known about the effect of biologic therapy on productivity costs. As healthcare costs have only been increasing, cost-effectiveness of biologics for IBD treatment might depend on their effect on productivity costs. Because considerable value can be gained by reducing productivity costs, the effects of biologic therapy on productivity should be further investigated.

4.3 | Patient costs

Patient costs from the societal perspective are relatively low compared to healthcare and productivity costs but might place a significant burden on patients. Because cost items are measured differently, a wide range of estimates are reported in the studies. Only eight studies in Europe estimated patient costs and contained little information on cost drivers, time trends or geographical differences.

4.4 | Limitations

This systematic review gives a detailed overview of the societal cost of illness of IBD. The review included studies in countries worldwide and did not focus on Western countries. However, some
FIGURE 5  Distribution of healthcare cost components in proportions per prevalent (A) inflammatory bowel disease, (B) Crohn's disease and (C) ulcerative colitis cases in 2018 US dollars.
limitations hamper the interpretability of results. For instance, geographic, socio-economic and political characteristics can affect costs. Differences in currency and purchasing power were resolved using the GDP deflator and PPP. However, considerable differences in healthcare systems, disease phenotype and other characteristics between countries and periods could have affected cost of illness comparisons.

There were considerable differences in populations and data sources in the studies. Even though the aim was to assess cost of illness of an IBD patient in clinical practice, some studies used different segments of the population. Moreover, how IBD cases were identified may have led to biased estimates. For instance, North American insurance-based studies often identified cases using insurance claims with ICD-9-CM codes for CD or UC with a 6-month pre-index period free of these codes.\(^{37,45,52,56,57,62}\) This method captures only active periods of treatment and can skew the estimates to a population with higher disease severity.

Not all studies included the same cost components, and valuation methods differed considerably. For example, North American studies often reported insurance claims as costs, possibly leading

---

**TABLE 2** Mean (range) annual IBD-attributable healthcare costs and component cost per prevalent case for CD and UC in 2018 US dollars per continent for the period 2010-2018

| Disease | Asia | Europe | North America |
|---------|------|--------|---------------|
| Healthcare costs | | | |
| CD | | | |
| N | 13 | 10 | 2 |
| Mean | $4417 | $12,439 | $17,495 |
| Min-Max | $1230-$31161 | $7694-$15,807 | $14,454-$20,535 |
| Inpatient | | | |
| N | 5 | 10 | 2 |
| Mean | $639 | $2,487 | $4,350 |
| Min-Max | $623-$664 | $1,575-$3,503 | $3,339-$5,360 |
| Outpatient | | | |
| N | 0 | 10 | 2 |
| Mean | — | $890 | $6,754 |
| Min-Max | — | $403-$1,112 | $4,496-$9,013 |
| Medication | | | |
| N | 7 | 10 | 2 |
| Mean | $1,777 | $9,048 | $5,796 |
| Min-Max | $1,342-$2,468 | $3,788-$12,013 | $5,016-$6,577 |
| UC | | | |
| Healthcare costs | | | |
| N | 13 | 9 | 1 |
| Mean | $1,606 | $7,224 | $13,559 |
| Min-Max | $309-$14,572 | $3,228-$9,779 | $13,559-$13,559 |
| Inpatient | | | |
| N | 5 | 9 | 1 |
| Mean | $187 | $1,236 | $3,874 |
| Min-Max | $171-$2,000 | $5,24-$19,56 | $3,874-$3,874 |
| Outpatient | | | |
| N | 0 | 9 | 1 |
| Mean | — | $746 | $5,307 |
| Min-Max | — | $499-$868 | $5,307-$5,307 |
| Medication | | | |
| N | 7 | 9 | 1 |
| Mean | $268 | $5,238 | $3,643 |
| Min-Max | $102-$4,83 | $1,936-$7,041 | $3,643-$3,643 |

Note: Costs do not sum as not all included studies reported all cost components separately. Abbreviations: —, no studies done; CD, Crohn’s disease; IBD, inflammatory bowel disease; N, number of observations; UC, ulcerative colitis.
to higher estimates.\textsuperscript{36,37,45,48,52,56,57,62,84,95} As most studies only reported costs and not resource use, it was not possible to determine if a difference in resource use explained cost differences or whether this was due to differing prices per resource. We aimed to reduce heterogeneity by stratifying studies based on disease and geographical area. These results should however be interpreted with caution because considerable differences in study methods remained. Further stratification on methodology, country or perspective would have led to non-informative groups, as only one or two studies per group would have remained. Currency and purchasing power transformation because considerable differences in study methods remained. Cross-sectional studies often differ in methodology through the years, impeding comparisons over time.

Currently, the number of international and longitudinal studies is lacking. No such studies on costs of prevalent IBD cases were found, and there were three reports from two European cohorts\textsuperscript{42,77,108} on costs of incident cases. The other longitudinal studies\textsuperscript{34,44,53,65,66,81} in this review did report information on changes in costs over time of prevalent cases but were limited by their focus on a single country.

5 | CONCLUSION

This comprehensive systematic review shows that the healthcare costs of IBD seem to be increasing on all continents, most likely driven by an increasing use of expensive medication. The decrease in inpatient costs that was expected with the introduction of biologic therapy was not seen in this review. To contain the rapidly growing costs, future initiatives should aim at optimising the use of biologic therapy in daily practice. Moreover, this review indicates that productivity costs possibly exceed healthcare costs and are a key societal cost driver for IBD. Because the cost-effectiveness of biologic therapy might mainly rely on the effect it has on work impairment, further research on this relationship is required. Lastly, longitudinal and international cost-of-illness studies on IBD are essential to validate these findings and clarify the global cost burden of IBD.

ACKNOWLEDGEMENTS

The authors would like to thank Helen West for language editing and proofreading of the manuscript.

Declaration of personal interests: Drs. van Linschoten, Drs. Visser, Prof. Dr. Hazelzet and Drs. Niehot have nothing to disclose. Prof. Dr. van der Woude reports personal fees from Abbvie and Celltrion, and grants from Pfizer and Janssen outside the submitted work. Dr. van Noord reports grants from AbbVie, Falk, Ferring, Janssen, MSD,
TABLE 4 Mean (range) productivity costs for IBD, CD and UC in 2018 US dollars per continent

| Continent     | IBD Mean | CD Mean | CD (incident) Mean | UC Mean | UC (incident) Mean |
|---------------|----------|---------|-------------------|---------|-------------------|
| Asia          |          |         |                   |         |                   |
| Absenteeism + Presenteeism |          |         |                   |         |                   |
| N             | 1        | 1       | 0                 | 1       | 0                 |
| Mean          | $4677    | $5638   | $4828             |         |                   |
| Min-Max       | $4677-$4677 | $5638-$5638 | $4828-$4828      |         |                   |
| Europe        |          |         |                   |         |                   |
| Absenteeism + Presenteeism |          |         |                   |         |                   |
| N             | 2        | 3       | 0                 | 3       | 0                 |
| Mean          | $7124    | $4485   | $6414             |         |                   |
| Min-Max       | $4795-$9452 | $4342-$10 243 | $2925-$11 619     |         |                   |
| Absenteeism   |          |         |                   |         |                   |
| N             | 3        | 6       | 7                 | 1       |                   |
| Mean          | $1338    | $2660   | $1956             | $2394   | $1677             |
| Min-Max       | $698-$2276 | $641-$5277 | $1956-$1956      | $651-$5992 | $1677-$1677 |
| Presenteeism  |          |         |                   |         |                   |
| N             | 2        | 2       | 0                 | 3       | 0                 |
| Mean          | $5636    | $3324   | $3828             |         |                   |
| Min-Max       | $4097-$7175 | $2420-$4228 | $1944-$5627      |         |                   |
| Early retirement + Disability |          |         |                   |         |                   |
| N             | 2        | 3       | 1                 | 2       | 1                 |
| Mean          | $1757    | $6661   | $5686             | $4478   | $3561             |
| Min-Max       | $1160-$2354 | $2508-$14 665 | $5686-$5686    | $2126-$6830 | $3561-$3561 |
| North America |          |         |                   |         |                   |
| Absenteeism + Presenteeism |          |         |                   |         |                   |
| N             | 1        | 0       | 0                 | 0       | 0                 |
| Mean          | $20 074  | —       | —                 | —       | —                 |
| Min-Max       | $20 074-$20 074 | —       | —                 | —       | —                 |
| Absenteeism   |          |         |                   |         |                   |
| N             | 3        | 3       | 0                 | 3       | 1                 |
| Mean          | $2074    | $752    | $1443             | $2266   |                   |
| Min-Max       | $916-$4310 | $307-$1303 | $85-$2350         | $2266-$2266 |                   |
| Presenteeism  |          |         |                   |         |                   |
| N             | 1        | 0       | 0                 | 0       | 0                 |
| Mean          | $15 764  | —       | —                 | —       | —                 |
| Min-Max       | $15 764-$15 764 | —       | —                 | —       | —                 |

Abbreviations: —, no studies done; CD, Crohn’s disease; IBD, inflammatory bowel disease; N, number of observations; UC, ulcerative colitis.

Pfizer, and Takeda and personal fees from Takeda and Janssen outside the submitted work. Dr. West reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, and Takeda and personal fees from AbbVie, Janssen, and Pfizer outside the submitted work.

AUTHORSHIP

Guarantor of the article: R.L. West and D. van Noord.

Author contributions: R.C.A. van Linschoten, D. van Noord and R.L. West designed the study. C.D. Niehot and R.C.A. van Linschoten performed the systematic search. R.C.A. van Linschoten and E. Visser analysed the data. R.C.A. van Linschoten, E. Visser, C.J. van der Woude, J.A. Hazelzet, D. van Noord and R.L. West interpreted the data. R.C.A. van Linschoten and E. Visser wrote the manuscript. All authors critically reviewed the manuscript and approved the final version of the manuscript for submission. R.L. West and D. van Noord share last authorship.

DATA AVAILABILITY STATEMENT

All data generated or analysed during this study are included in this published article and its supplementary information files.
REFERENCES

1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.

2. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214.

3. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

4. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.

5. Yu H, Machaas D, Wong JJ, et al. Market share and costs of biological therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47:364–370.

6. Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECISE 2 study. Aliment Pharmacol Ther. 2010;31:1276–1285.

7. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228–1239.

8. Feagan BG, Sandborn WJ, Lazar A, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014;146:110–118.e3.

9. Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19:2098–2110.

10. van der Valk ME. Costs of inflammatory bowel disease in the Netherlands: the COIN study [PhD thesis]. Utrecht University, 2015.

11. World Health Organization. Global health expenditure database. 2019; https://apps.who.int/nha/database/Select/Indicators/en.

12. Organisation for Economic Co-operation and Development. Health spending (indicator). 2019, 2019. https://data.oecd.org/healthres/health-spending.htm.

13. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–328.

14. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.

15. Busch K, da Silva SA, Holton M, Rabacow FM, Khalili H, Ludvigsson JF. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2014;8:1362–1377.

16. Constantin J, Atanasov P, Wirth D, Borsi A. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. BMC Gastroenterol. 2019;19:179.

17. Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn’s disease and ulcerative colitis. A systematic review. Arch Med Sci. 2016;12:295–302.

18. Kawalec P, Malinowski KP. Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis. Expert Rev Pharmacoeconomics Outcomes Res. 2015;15:253–266.

19. El-Matary W, Kuenzig ME, Singh H, et al. Disease-associated costs in children with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2020;26:206–215.

20. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.

21. Byford S, Raftery J. Perspectives in economic evaluation. BMJ. 1998;316:1529–1530.

22. Moher D, Liberati A, Tetzlaff J, Altman DG Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

23. Visser E, van Linschoten RCA, West RL, van Noord D, Hazelzet JA, van der Woode CJ. Cost of illness of inflammatory bowel disease: a systematic review, 2020. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=158567.

24. Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of google scholar in evidence reviews and its applicability to grey literature searching. PLoS One. 2015;10:e0138237.

25. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–671.

26. Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53:175–196.

27. The World Bank. World Development Indicators. 2020; https://databank.worldbank.org/reports.aspx?source=2&series=PPP.PA.NUS.PPPP.RF.PX.REX.REER.NY.GDP.DEFL.ZS.FP.CPI.TOTL#.

28. Organisation for Economic Co-operation and Development. Purchasing power parities (PPP), 2019; https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm.

29. Organisation for Economic Co-operation and Development. GDP deflators, forecast growth. 2019. https://stats.oecd.org/Index.asp?QueryId=61354.

30. National Statistics Republic of China (Taiwan). Statistical Tables. 2020; https://eng.stat.gov.tw/ct.asp?xItem=37408&CntNode=5347&mp=5.

31. Census and Statistics Department The Government of the Hong Kong Special Administrative Region. Table 030: Gross Domestic Product (GDP), implicit price deflator of GDP and per capita GDP. 2020; https://www.censtatd.gov.hk/kstat/sub/sp250.jsp?tableID=030&ID=0&productType=8.

32. Aldeguer X, Sicras-Mainar A. Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: a database study. Gastroenterol Hepatol. 2016;39:9–19.

33. Bahler C, Schoepfer AM, Vavricka SR, Brungger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29:916–925.

34. Bahler C, Vavricka SR, Schoepfer AM, Brungger B, Reich O. Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol. 2017;17:138.

35. Bassi A, Dodd S, Williamson P, Bogder K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471–1478.

36. Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18:1498–1508.

37. Bickston SJ, Waters HC, Dabbous O, Tang B, Rahman MI. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008;14:352–362.

38. Blomqvist P, Ekborn A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32:1134–1139.

39. Blomqvist P, Feltelius N, Löfberg R, Ekborn A. A 10-year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions. Aliment Pharmacol Ther. 2001;15:475–481.

40. Blumenstein I, Bock H, Weber C, et al. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main
cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719–728.
78. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016;111:15–23.
79. Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020;26:1–10.
80. Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ. 2014;2:e587.
81. Pillai N, Dusheiko M, Maillard MH, et al. The evolution of health care utilisation and costs for inflammatory bowel disease over ten years. J Crohns Colitis. 2019;13:744–754.
82. Pinchbeck BR, Kirdeikis J, Thomson ABR. Economic impact of inflammatory bowel disease in Alberta. J Gastroenterol Hepatol. 1988;2:53–56.
83. Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011;12:273–283.
84. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.
85. Severs M, Petersen RE, Siersema PD, Mangen MJ, Oldenburg B. Self-reported health care utilization of patients with inflammatory bowel disease correlates perfectly with medical records. Inflamm Bowel Dis. 2016;22:688–693.
86. Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24:797–814.
87. van der Valk ME, Mangen M-J, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63:72–79.
88. van der Valk ME, Mangen M-J, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11:e0142481.
89. Yamabe K, Liebert R, Flores N, Pashos CL. Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan. Clinicoecom Outcomes Res. 2019;11:221–232.
90. Zand A, van Deen WK, Inserua EK, et al. Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact. Inflamm Bowel Dis. 2015;21:1623–1630.
91. Balaii H, Olfatifar M, Narab SO, Hosseini AA, Salehi AS, Shahrokh S. Estimation the direct cost of inflammatory bowel disease in Iranian patients: the one-year follow-up. Gastroenterol Hepatol Bed Bench. 2019;12:587–593.
92. Burisch J, Vardi H, Schwartz D, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5:454–464.
93. Vadstrup K, Alulis S, Borsi A, et al. Societal costs attributable to Crohn’s disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002–2016. Scand J Gastroenterol. 2020;55:41–46.
94. van Gennep S, Evers SW, Rietdijk ST, et al. High disease burden drives indirect costs in employed inflammatory bowel disease patients: the WORK-IBD study. Inflamm Bowel Dis. 2021;27:352–363.
95. Dillon D, Ding Z, Muser E, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin. 2020;36:1285–1294.
96. Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Sieber S. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020;79:771–777.
97. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
98. Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease [CALM]: a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779–2789.
99. Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.
100. Jeuring SFG, Bours PHA, Zegers MP, et al. Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis. 2015;9:837–845.
101. Jeuring SFG, van den Heuvel TRA, Liu LYL, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112:325–336.
102. Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020;69:274–282.
103. Koopmanschap MA, Rutten FF, van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171–189.
104. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31:537–549.
105. Nymann JA. Productivity costs revisited: toward a new US policy. Health Econ. 2012;21:1387–1401.
106. Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16:765–778.
107. van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–91.
108. Fiorino G, Lytras T, Younge L, et al. Quality of care standards in inflammatory bowel diseases: a European Crohn’s and Colitis Organisation (ECCO) position paper. J Crohns Colitis. 2020;14:1037–1048.
109. Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45:1043–1057.
110. Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019;50:269–277.

**SUPPORTING INFORMATION**

Additional supporting information will be found online in the Supporting Information section.

How to cite this article: van Linschoten RCA, Visser E, Nieholt CD, et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021;54:234–248. [https://doi.org/10.1111/apt.16445](https://doi.org/10.1111/apt.16445)